Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
Wagener-Ryczek S et al. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer 2020; May 12;20(1):408. doi: 10.1186/s12885-020-06920-3